TABLE 3.
Means and 95% CIs or medians and ranges for pharmacokinetic variables for acute- and convalescent-phase oral administrationa
| Variable | Acute phaseb | Convalescent phaseb | P value |
|---|---|---|---|
| No. of subjects | 19 | 15 | |
| AIC | 158 (148–168) | 130 (118–142) | |
| Tmax (h) | 0.75 (0.50–4.00)c | 1.00 (0.50–4.00)c | NS |
| Cmax (ng/ml) | 1,021 (775–1267) | 546 (379–715) | 0.013 |
| Tlag (h) | 0.30 (0.16–0.44) | 0.36 (0.18–0.54) | NS |
| t1/2 (h) | 0.71 (0.55–0.87) | 0.84 (0.49–1.09) | NS |
| k01 (h−1) | 1.86 (0.80–20.87)c | 3.44 (0.60–29.52)c | NS |
| k10 (/h−1) | 1.13d (0.96–1.30) | 1.08d (0.78–1.38) | NS |
| V/f (liters/kg) | 1.33d (1.02–1.64) | 3.15d (2.02–4.28) | 0.005 |
| CL/f (liters/kg/h) | 1.38d (1.03–1.73) | 2.54d (2.10–2.98) | 0.003 |
| AUC0–24 (ng · h/ml) | 1,738d (1,412–2,064) | 886d (733–1,039) | 0.0005 |
Bioassay results are in DHA equivalents. Abbreviations are the same as defined in footnote a of Table 2 and as follows: AIC, Akaike Information Criterion; Tmax, observed time to Cmax; Cmax, maximum observed concentration; Tlag, absorption lag time; k01, absorption rate constant; V/f, total apparent volume of distribution per kilogram of body weight; f, fraction of the oral drug that is absorbed; NS, not significant. Values are means (95% CIs) unless indicated otherwise.
To convert DHA equivalents in nanograms to milliliter to nanomoles per liter, multiply by 3.517.
Values are medians (ranges).
Significantly (P < 0.01) different from mean for acute-phase intravenous administration (Table 2). For oral and convalescent-phase volume of distribution data compared with the estimated steady-state volume of distribution data, P was not significant P > 0.02.